Olaparib – cancer de prostate métastatique résistant à la castration muté BRCA
- 3 February 2021
- journal article
- editorial
- Published by Elsevier BV in Bulletin du Cancer
- Vol. 108 (2), 140-142
- https://doi.org/10.1016/j.bulcan.2020.11.010
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Survival with Olaparib in Metastatic Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2020
- Nouvelle AMM : olaparib — cancer du pancréas avec mutation germinale de BRCABulletin du Cancer, 2020
- Olaparib for Metastatic Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2020
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialThe Lancet Oncology, 2020
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate CancerThe New England Journal of Medicine, 2019
- Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostateProgrès en Urologie, 2018
- Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision MakingJCO Precision Oncology, 2017
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate CancerThe New England Journal of Medicine, 2016
- Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate CancerJournal of Clinical Oncology, 2013
- Molecular Pathways: Targeting PARP in Cancer TreatmentClinical Cancer Research, 2013